Isis Pharmaceuticals, Inc., is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company’s primary activity is to discover and develop antisense drugs. The antisense drugs are used to treat a wide range of diseases, including severe and rare, cardiovascular, neurologic and metabolic diseases and cancer. The Company’s flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies As of December 2013 The Company has three generation 2.5 drugs in development, ISIS-STAT3Rx, ISIS-ARRx and ISIS-FVIIRx. As of December 2013 the Company has a pipeline of 31 drugs in development.